1
0
0
News
Zelluna Immunotherapy appoints Jens-Pete...Zelluna Immunotherapy AS
www.zelluna.com
— Jens-Peter Marschner is a medical doctor bringing to Zelluna more than 20 years experience in clinical development and medical affairs with a — Jens-Peter Marschner is a medical doctor bringing to Zelluna more than 20 years experience in clinical development and medical affairs with a ...
News > United StatesLife-Sciences-USA.com
www.life-sciences-usa.com
"Press Release: Zelluna Immunotherapy Appoints Jens-Peter Marschner as Chief Medical Officer". Oslo Zelluna Immunotherapy AS. ( ). "Press ... "Press Release: Zelluna Immunotherapy Appoints Jens-Peter Marschner as Chief Medical Officer". Oslo Zelluna Immunotherapy AS. ( ). "Press ...
März 2020Stadt Bensheim
www.bensheim.de
— Jens-Peter Marschner,. Facharzt für Klinische Pharmakologie. Sanner-Forum, . Bensheim-Auerbach — Jens-Peter Marschner,. Facharzt für Klinische Pharmakologie. Sanner-Forum, . Bensheim-Auerbach ...
Affimed Reports Financial Results for Second Quarter 2016
www.globenewswire.com
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px;...
Netzwerk-Profile
LinkedIn: Jens-Peter Marschner | Berufsprofil - LinkedIn
Jens-Peter Marschners berufliches Profil anzeigen LinkedIn ist das weltweit größte professionelle Netzwerk, das Fach- und Führungskräften wie Jens-Peter ...
Firmen-Mitarbeiter
AbbVie Komplementär GmbH - Life-Sciences-Germany.comlife-sciences-germany.com
www.life-sciences-germany.com
[6] Zelluna Immunotherapy AS. ( ). "Press Release: Zelluna Immunotherapy Appoints Jens-Peter Marschner as Chief Medical Officer". Oslo.... [7] AbbVie ... [6] Zelluna Immunotherapy AS. ( ). "Press Release: Zelluna Immunotherapy Appoints Jens-Peter Marschner as Chief Medical Officer". Oslo.... [7] AbbVie ...
Zelluna Immunotherapy ASLife-Sciences-Europe.com
www.life-sciences-europe.com
"Press Release: Zelluna Immunotherapy Appoints Jens-Peter Marschner as Chief Medical Officer". Oslo.... [8] Zelluna Immunotherapy AS. ( ). "Press ... "Press Release: Zelluna Immunotherapy Appoints Jens-Peter Marschner as Chief Medical Officer". Oslo.... [8] Zelluna Immunotherapy AS. ( ). "Press ...
Ausbildung
Jens Peter Marschner - Biography
www.marketscreener.com
Dr. Jens Peter Marschner, MD, is Chief Medical Officer at Affimed NV.
He received his doctorate degree from Johann Wolfgang Goethe-Universität Frankfurt am...
Bücher
DNB, Katalog der Deutschen NationalbibliothekDeutsche Nationalbibliothek
portal.dnb.de
... Jens-Peter Marschner, Michael J Mastrangelo, Giuseppe Masucci, Ignacio Melero, Cornelius Melief, William J Murphy, Brad Nelson, Andrea Nicolini, Michael I Jens-Peter Marschner, Michael J Mastrangelo, Giuseppe Masucci, Ignacio Melero, Cornelius Melief, William J Murphy, Brad Nelson, Andrea Nicolini, Michael I ...
Cancer Vaccines - Google Books
books.google.de
This volume focuses on the laboratory and clinical experience with targeting viral onco-antigens, while also reviewing the approaches to targeting self-cancer...
Klinische Pharmakologie: Arzneitherapie - Google Books
books.google.de
Die komplexen Systeme des menschlichen Organismus und seiner Kontrollmechanismen setzen heute beim Arzt ein großes Arzneimittelwissen voraus, das permanent...
Klinische Pharmakologie: Ein Leitfaden für die Praxis - Google Books
books.google.de
Dieser Leitfaden Klinische Pharmakologie hat sich für den Arzt als Ratgeber bei der Verordnung von Arzneimitteln und für den Studenten der Humanmedizin als...
Dokumente zum Namen
Efficacy and safety of an intravenous monoclonal anti‐HBs ...Wiley Online Library
onlinelibrary.wiley.com
von AB Van Nunen · · Zitiert von: 19 — Jens-Peter Marschner,. Jens-Peter Marschner. Department of Clinical Development, Boehringer Mannheim GmbH, Mannheim, Germany. Search for more ... von AB Van Nunen · · Zitiert von: 19 — Jens-Peter Marschner,. Jens-Peter Marschner. Department of Clinical Development, Boehringer Mannheim GmbH, Mannheim, Germany. Search for more ...
Abstract 2323: Immune checkpoint inhibition by anti-PD-1 or ...aacrjournals.org
aacrjournals.org
— Jens-Peter Marschner;. Jens-Peter Marschner. 2Affimed GmbH, Heidelberg, Germany. Search for other works by this author on: This Site · PubMed — Jens-Peter Marschner;. Jens-Peter Marschner. 2Affimed GmbH, Heidelberg, Germany. Search for other works by this author on: This Site · PubMed.
Immunotherapy Europe Speakers - The Perfect Combination of Strategy a…
de.slideshare.net
Phacilitate's Immunotherapy Europe will bring leaders in the field together. big phama, biotech, payers, HTAs, regulators and investors. See what's being discu…
OASIS
www.abstractsonline.com
Achim Rothe, Katrin S. Reiners, Max S. Topp, Anas Younes, Bastian von Tresckow, Horst Dieter Hummel, Joerg Kessler, Miroslav Ravic, Jens-Peter Marschner, ...
Wissenschaftliche Veröffentlichungen
CD30/CD16A Tandab AFM13-Induced Target Cell Lysis By ...ScienceDirect.com
www.sciencedirect.com
von X Zhao · · Zitiert von: 5 — ... Jens-Peter Marschner , MD,*,3 Martin Treder ,*,3 Holbrook Kohrt , MD4 1Center for Clinical Sciences Research Stanford, Stanford University ... von X Zhao · · Zitiert von: 5 — ... Jens-Peter Marschner , MD,*,3 Martin Treder ,*,3 Holbrook Kohrt , MD4 1Center for Clinical Sciences Research Stanford, Stanford University ...
Defining the critical hurdles in cancer immunotherapyJournal of Translational Medicine
translational-medicine.biomedcentral.com
Fox, Andrea Nicolini, Jens-Peter Marschner, Tanja de Gruijl, Brad Nelson, Axel Hoos, Tetsuro Sasada, Yutaka Kawakami, Rejean Lapointe, Christoph Huber, Jonathan ... Fox, Andrea Nicolini, Jens-Peter Marschner, Tanja de Gruijl, Brad Nelson, Axel Hoos, Tetsuro Sasada, Yutaka Kawakami, Rejean Lapointe, Christoph Huber, Jonathan ...
Defining the critical hurdles in cancer immunotherapyHAL-Inserm
inserm.hal.science
... Jens-Peter Marschner (64) , Michael Mastrangelo (65) , Giuseppe Masucci (66) , Ignacio Melero (67) , Cornelius Melief (68) , William Murphy (69) , Brad Jens-Peter Marschner (64) , Michael Mastrangelo (65) , Giuseppe Masucci (66) , Ignacio Melero (67) , Cornelius Melief (68) , William Murphy (69) , Brad ...
Specific NK Cell Activation to Treat Relapsed/Refractory (r/ ...ScienceDirect.com
www.sciencedirect.com
von A Rothe · · Zitiert von: 2 — ... Jens-Peter Marschner, MD,*,8 Andreas Engert, MD9 1University Hospital of Cologne, Cologne, Germany 2University Hospital of Cologne, Cologne ... von A Rothe · · Zitiert von: 2 — ... Jens-Peter Marschner, MD,*,8 Andreas Engert, MD9 1University Hospital of Cologne, Cologne, Germany 2University Hospital of Cologne, Cologne ...
Veröffentlichungen allgemein
Journal of Translational MedicineCORE
core.ac.uk
von BA Fox · · Zitiert von: 187 — Jens-Peter Marschner (). Michael J Mastrangelo (). Giuseppe Masucci (giuseppe ... von BA Fox · · Zitiert von: 187 — Jens-Peter Marschner (). Michael J Mastrangelo (). Giuseppe Masucci (giuseppe ...
WORKSHOPwebhosting.be
cddforg.webhosting.be
Jens-Peter Marschner (Merck Serono, Germany). Giovanni Migliaccio (Istituto Superiore di Sanità, Italy). 16:15. Biomarker strategies for vaccine department ... Jens-Peter Marschner (Merck Serono, Germany). Giovanni Migliaccio (Istituto Superiore di Sanità, Italy). 16:15. Biomarker strategies for vaccine department ...
Defining the critical hurdles in cancer immunotherapy | SpringerLink
link.springer.com
Scientific discoveries that provide strong evidence of antitumor effects in preclinical models often encounter significant delays before being tested in...
Artikel & Meinungen
Twitter-Nachrichten: Miguel ForteX
Zelluna - News. Jens-Peter Marschner appointed as Zelluna CMO. Important addition to Zelluna team in our path to deliver value to patients with solid ... Zelluna - News. Jens-Peter Marschner appointed as Zelluna CMO. Important addition to Zelluna team in our path to deliver value to patients with solid ...
Affimed to Host Hodgkin's Lymphoma Day with Key Opinion ...CNN
money.cnn.com
— The discussion will be moderated by Affimed's Chief Medical Officer, Jens-Peter Marschner, M.D., and the Company's Chief Scientific Officer, — The discussion will be moderated by Affimed's Chief Medical Officer, Jens-Peter Marschner, M.D., and the Company's Chief Scientific Officer, ...
Affimed Announces Addition of Dr. Andrew Evens to Scientific ...CNN
money.cnn.com
— Evens to our Scientific Advisory Board," said Jens-Peter Marschner, M.D., CMO of Affimed. "Dr. Evens brings invaluable expertise in the — Evens to our Scientific Advisory Board," said Jens-Peter Marschner, M.D., CMO of Affimed. "Dr. Evens brings invaluable expertise in the ...
People | Nature BiotechnologyNature
www.nature.com
von N Azie — Oslo-based Zelluna Immunotherapy has named Jens-Peter Marschner as chief medical officer. Marschner is a medical doctor who brings more than ... von N Azie — Oslo-based Zelluna Immunotherapy has named Jens-Peter Marschner as chief medical officer. Marschner is a medical doctor who brings more than ...
Sonstiges
CD30XCD16A antitest kombinálása anti-PD-1-antagonista ...Google Patents
patents.google.com
Jens-Peter Marschner: Stefan Knackmuss. Worldwide applications AU. Application number: AU A. Filing date: Legal status: Active. EP. Jens-Peter Marschner: Stefan Knackmuss. Worldwide applications AU. Application number: AU A. Filing date: Legal status: Active. EP.
Kombinacija anti-cd30xcd16a antitela sa antagonističkim ...Google Patents
patents.google.com
Jens-Peter Marschner: Stefan Knackmuss. Worldwide applications CA. Application number: CA A. Filing date: Legal status: Active. HU. Jens-Peter Marschner: Stefan Knackmuss. Worldwide applications CA. Application number: CA A. Filing date: Legal status: Active. HU.
Jens-Peter Marschner | Scholar Profiles and RankingsScholarGPS
scholargps.com
Jens-Peter Marschner ; Affiliation. Goethe University, Frankfurt am Main, Germany ; Field. Medicine ; Discipline. Gastroenterology ; Top Specialties. Intravenous ... Jens-Peter Marschner ; Affiliation. Goethe University, Frankfurt am Main, Germany ; Field. Medicine ; Discipline. Gastroenterology ; Top Specialties. Intravenous ...
Jens-Peter Marschner's research worksResearchGate
www.researchgate.net
Citation Format: Xing Zhao, Narendiran Rajasekaran, Uwe Reusch, Jens-Peter Marschner, Martin Treder, Holbrook E. Kohrt. Immune checkpoint inhibition by anti ... Citation Format: Xing Zhao, Narendiran Rajasekaran, Uwe Reusch, Jens-Peter Marschner, Martin Treder, Holbrook E. Kohrt. Immune checkpoint inhibition by anti ...
Experiences of Jens Peter Marschner: Current and past positions ...marketscreener.com
ca.marketscreener.com
Find out more about Jens Peter Marschner's international, operational and industry experience. 2 positions known in addition to at. Find out more about Jens Peter Marschner's international, operational and industry experience. 2 positions known in addition to at.
Jens Peter Marschner: Positions, Relations and NetworkMarketScreener
ca.marketscreener.com
Dr. Jens Peter Marschner, MD, is Chief Medical Officer at Affimed NV. He received his doctorate degree from Johann Wolfgang Goethe-Universität Frankfurt am Main ... Dr. Jens Peter Marschner, MD, is Chief Medical Officer at Affimed NV. He received his doctorate degree from Johann Wolfgang Goethe-Universität Frankfurt am Main ...
Jens-Peter Marschner - Health and MedicineGale
go.gale.com
— Gale OneFile includes Jens-Peter Marschner by . Read the beginning or sign in for the full text — Gale OneFile includes Jens-Peter Marschner by . Read the beginning or sign in for the full text.
A phase 1 study of the bispecific anti-CD ASH Publicationsashpublications.org
ashpublications.org
Jens-Peter Marschner,. Jens-Peter Marschner. 5Affimed, Heidelberg, Germany. Search for other works by this author on: This Site · PubMed · Google Scholar. Elke ... Jens-Peter Marschner,. Jens-Peter Marschner. 5Affimed, Heidelberg, Germany. Search for other works by this author on: This Site · PubMed · Google Scholar. Elke ...
A phase 1 study of the bispecific anti-CD30/CD16A ...Europe PMC
europepmc.org
von A Rothe · · Zitiert von: 307 — ... Jens-Peter Marschner. 5Affimed, Heidelberg, Germany. Find articles by Jens-Peter Marschner. Elke Pogge von Strandmann. 2Innate Immunity Group, Department I of ... von A Rothe · · Zitiert von: 307 — ... Jens-Peter Marschner. 5Affimed, Heidelberg, Germany. Find articles by Jens-Peter Marschner. Elke Pogge von Strandmann. 2Innate Immunity Group, Department I of ...
ATX-101, a cell-penetrating protein targeting PCNA, can be ...Europe PMC
europepmc.org
von CR Lemech · · Zitiert von: 13 — ... Jens-Peter Marschner. 3Therapim Pty Ltd, Southport, QLD Australia. Find articles by Jens-Peter Marschner. Konstantinos Alevizopoulos. 3Therapim Pty Ltd ... von CR Lemech · · Zitiert von: 13 — ... Jens-Peter Marschner. 3Therapim Pty Ltd, Southport, QLD Australia. Find articles by Jens-Peter Marschner. Konstantinos Alevizopoulos. 3Therapim Pty Ltd ...
ATX-101, a cell-penetrating protein targeting PCNA, can be ...National Institutes of Health (NIH) (.gov)
pubmed.ncbi.nlm.nih.gov
von CR Lemech · · Zitiert von: 13 — Jens-Peter Marschner , Konstantinos Alevizopoulos , Marit Otterlei , Michael Millward. Affiliations. 1 Scientia Clinical Research ... von CR Lemech · · Zitiert von: 13 — Jens-Peter Marschner , Konstantinos Alevizopoulos , Marit Otterlei , Michael Millward. Affiliations. 1 Scientia Clinical Research ...
ATX-101, a cell-penetrating protein targeting PCNA, can be ...The University of Western Australia
research-repository.uwa.edu.au
von CR Lemech · · Zitiert von: 13 — Charlotte Rose Lemech, Ganessan Kichenadasse, Jens-Peter Marschner, Konstantinos Alevizopoulos, Marit Otterlei, Michael Millward · Internal ... von CR Lemech · · Zitiert von: 13 — Charlotte Rose Lemech, Ganessan Kichenadasse, Jens-Peter Marschner, Konstantinos Alevizopoulos, Marit Otterlei, Michael Millward · Internal ...
Affimed N.V. Niederlassung Deutschland, MannheimCompanyhouse
www.companyhouse.de
Nicht mehr: Vorstand (Bestuurder): Jens-Peter Marschner, a Bestellt aufgrund Formwechsel als Vorstand (Bestuurder): Florian Heinz Martin Fischer, München; ... Nicht mehr: Vorstand (Bestuurder): Jens-Peter Marschner, a Bestellt aufgrund Formwechsel als Vorstand (Bestuurder): Florian Heinz Martin Fischer, München; ...
Affimed NVSEC.gov
www.sec.gov
As part of the Option Grant, Adi Hoess received 290,000 stock options, Florian Fischer received 105,000 stock options and Jens-Peter Marschner received 80, As part of the Option Grant, Adi Hoess received 290,000 stock options, Florian Fischer received 105,000 stock options and Jens-Peter Marschner received 80,
Affimed to Speak at Symposium on Emerging Approaches ...PM360
www.pm360online.com
... Jens-Peter Marschner, will present at the symposium titled “Emerging Approaches in Cancer Immunotherapy” in New York City on Monday, February 29 at 12: Jens-Peter Marschner, will present at the symposium titled “Emerging Approaches in Cancer Immunotherapy” in New York City on Monday, February 29 at 12:
AppointmentsEuropean Biotechnology
european-biotechnology.com
Jens-Peter Marschner joins Zelluna. Zelluna Immunotherapy, a biotechnology company specializing in T-cell receptor (TCR) immunotherapies,... MORE Jens-Peter Marschner joins Zelluna. Zelluna Immunotherapy, a biotechnology company specializing in T-cell receptor (TCR) immunotherapies,... MORE
Cancer VaccinesAltmetric
link.altmetric.com
_2014_428. Pubmed ID Book ISBNs , Authors. Sonia Quaratino, Ulf Forssmann, Jens-Peter Marschner _2014_428. Pubmed ID Book ISBNs , Authors. Sonia Quaratino, Ulf Forssmann, Jens-Peter Marschner.
Defining the critical hurdles in cancer 中国地质图书馆中国地质图书馆
36.112.18.19
Jens-Peter Marschner (68) Michael J Mastrangelo (69) Giuseppe Masucci (70) Ignacio Melero (71) Cornelius Melief (72) William J Murphy (73) Brad Nelson (74) Jens-Peter Marschner (68) Michael J Mastrangelo (69) Giuseppe Masucci (70) Ignacio Melero (71) Cornelius Melief (72) William J Murphy (73) Brad Nelson (74)
Defining the critical hurdles in cancer immunotherapy.Europe PMC
europepmc.org
von BA Fox · · Zitiert von: 187 — ... Jens-Peter Marschner,68 Michael J Mastrangelo,69 Giuseppe Masucci,70 Ignacio ... Jens-Peter Marschner, Tanja de Gruijl, Brad Nelson, Axel Hoos, Tetsuro ... von BA Fox · · Zitiert von: 187 — ... Jens-Peter Marschner,68 Michael J Mastrangelo,69 Giuseppe Masucci,70 Ignacio ... Jens-Peter Marschner, Tanja de Gruijl, Brad Nelson, Axel Hoos, Tetsuro ...
EMD in Montanide ISA 51 VG Administered ...ClinicalTrials.gov
classic.clinicaltrials.gov
Jens-Peter Marschner, MD, Merck KGaA, Darmstadt. More Information. Go to sections. Top of Page Study Description Study Design Arms and Interventions Outcome ... Jens-Peter Marschner, MD, Merck KGaA, Darmstadt. More Information. Go to sections. Top of Page Study Description Study Design Arms and Interventions Outcome ...
Verwandte Suchanfragen zu Jens-Peter Marschner
sortiert nach Relevanz / Datum